文献速递中毒与环境急症儿科与产科急症

儿童摄入维拉佐酮与其他选择性5-羟色胺再摄取抑制剂的比较

Pediatric ingestion of vilazodone compared to other selective serotonin reuptake inhibitor medications.
PubMed 文献 · Clin Toxicol (Phila) · 2017-02-13
一句话结论儿童摄入维拉佐酮后住院率和严重临床结局均高于其他SSRI,现有SSRI暴露管理指南可能不适用于该药。

该研究为回顾性观察性病例系列分析,基于美国国家中毒数据系统(NPDS)2012年1月至2016年6月报告的11,384例6岁以下儿童SSRI暴露数据。维拉佐酮仅占全部暴露的5.9%,但单药暴露(531例中165例,31.1%;OR 9.0 [7.3-11.2])和多药暴露(107例中57例,53.3%;OR 4.1 [2.7-6.2])的医疗机构入住比例均最高。维拉佐酮暴露儿童发生中重度结局的比值也更高:单药暴露为531例中134例(25.2%;OR 20.5 [15.5-27.1]),多药暴露为107例中37例(35.6%;OR 5.9 [3.7-9.0])。癫痫发作和昏迷等严重临床结局在维拉佐酮暴露中更常见。作者认为现有证据-based SSRI暴露管理指南可能不适用于该年龄段维拉佐酮摄入的处理。

要点

  • 6岁以下儿童维拉佐酮单药暴露的入院率为31.1%(165/531),OR 9.0(95%CI 7.3-11.2),高于其他SSRI。
  • 维拉佐酮单药暴露发生中重度结局的比例为25.2%(134/531),OR 20.5(95%CI 15.5-27.1)。
  • 维拉佐酮多药暴露的入院率为53.3%(57/107),OR 4.1(95%CI 2.7-6.2),中重度结局比例为35.6%(37/107),OR 5.9(95%CI 3.7-9.0)。
  • 癫痫发作和昏迷等严重临床结局在维拉佐酮暴露中更常见。
  • 作者认为现有SSRI暴露管理指南可能不适用于该年龄段维拉佐酮摄入的处理。

适用人群与场景

  • 6岁以下儿童,因单药或多药SSRI暴露报告至美国国家中毒数据系统(NPDS)。

红旗征与不能漏的情况

  • 维拉佐酮暴露儿童中癫痫发作和昏迷等严重临床结局更常见。

研究设计与关键结果

  • 研究类型:回顾性观察性病例系列分析;数据来源:美国国家中毒数据系统(NPDS);时间范围:2012年1月至2016年6月;样本量:11,384例6岁以下儿童SSRI暴露。
  • 维拉佐酮占全部SSRI暴露的5.9%。
  • 单药暴露:维拉佐酮组入院165/531(31.1%),OR 9.0(95%CI 7.3-11.2);多药暴露:维拉佐酮组入院57/107(53.3%),OR 4.1(95%CI 2.7-6.2),均高于其他SSRI。
  • 单药暴露:维拉佐酮组中重度结局134/531(25.2%),OR 20.5(95%CI 15.5-27.1);多药暴露:维拉佐酮组中重度结局37/107(35.6%),OR 5.9(95%CI 3.7-9.0),均高于其他SSRI。
  • 癫痫发作和昏迷等严重临床结局在维拉佐酮暴露中更常见。

证据类型、等级与局限

  • 证据类型:回顾性观察性病例系列分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为现有基于证据的SSRI暴露管理指南可能不适用于该年龄段维拉佐酮摄入的处理。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Unintentional ingestion of selective serotonin reuptake inhibitor (SSRI) medications is common amongst children <6 years of age. Current evidence-based management guidelines are based on a low incidence of significant medical outcomes in these children.

OBJECTIVE: To describe and compare outcomes of pediatric exposures to vilazodone with other SSRIs.

METHODS: A retrospective observational case series analysis of both single and polysubstance SSRI exposures amongst children <6 years old reported to the National Poison Data System (NPDS).

RESULTS: 11,384 SSRI exposures in children <6 years of age reported to NPDS between January 2012 and June 2016 were assessed. Vilazodone only accounted for 5.9% of all exposures, but resulted in the highest proportion of health care facility admission compared to other SSRIs, both in single substance (165 of 531 (31.1%); OR 9.0 [7.3-11.2]) and polysubstance (57 of 107 (53.3%); OR 4.1 [2.7-6.2]) exposures. Children exposed to vilazodone also have higher odds of experiencing a major or moderate outcome in single (134 of 531 (25.2%); OR 20.5 [15.5-27.1]) and polysubstance (37 of 107 (35.6%); OR 5.9 [3.7-9.0]) exposures compared to other SSRIs. Several severe clinical outcomes, such as seizure and coma, were more common among the vilazodone exposures.

CONCLUSIONS: Exposure to vilazodone in this age group results in an increased rate of hospitalization as well as more severe clinical effects as compared to other SSRIs. Current evidence-based SSRI exposure management guidelines may not be appropriate for the management of vilazodone ingestion in this age group.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Russell JL, Spiller HA, Chounthirath T, et al. Pediatric ingestion of vilazodone compared to other selective serotonin reuptake inhibitor medications. Clin Toxicol (Phila). 2017. PMID: 28421837. doi:10.1080/15563650.2017.1287375

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。